Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 7/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 8/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657812 | 1.00 | ITGA4 (0.44) | ITGA4ITGB1POLBMC4RTACR1 | |
| SCHEMBL5972730 | 1.00 | ITGA4 (0.44) | ITGA4ITGB1POLBMC4RTACR1 | |
| SCHEMBL13602359 | 0.89 | MC4R (0.43) | ITGA4ITGB1POLBMC4RTACR1 | |
| SCHEMBL830668 | 0.88 | POLB (0.56) | POLBMC4RTACR1LMNA | |
| SCHEMBL2297284 | 0.88 | POLB (0.56) | POLBMC4RTACR1LMNA | |
| SCHEMBL830669 | 0.88 | POLB (0.56) | POLBMC4RTACR1LMNA | |
| SCHEMBL5973120 | 0.84 | RIPK1 (0.50) | ITGA4ITGB1MC4RTACR1LMNA | |
| SCHEMBL22926184 | 0.84 | MC4R (0.51) | POLBMC4R | |
| SCHEMBL20805978 | 0.84 | MC4R (0.51) | POLBMC4R | |
| SCHEMBL7546130 | 0.83 | MC4R (0.41) | POLBMC4RTACR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265146-B2 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2007-09-04 | — | — | US | claimed |
| US-20050187284-A1 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2005-08-25 | — | — | US | claimed |
| EP-1330430-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2003-07-30 | — | — | EP | claimed |
| US-20020035104-A1 | Integrin receptor inhibitors | GENENTECH, INC. | 2002-03-21 | — | — | US | claimed |
| WO-2002016313-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2002-02-28 | — | — | WO | claimed |
| US-7265146-B2 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20060234306-A1 | Assay method | GENENTECH, INC. (US) | 2006-10-19 | — | — | US | disclosed |
| US-20050233387-A1 | Assay method | GENENTECH, INC. (US) | 2005-10-20 | — | — | US | disclosed |
| US-20050187284-A1 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| US-6933314-B2 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-20040077693-A1 | Integrin receptor inhibitors | GENENTECH, INC. | 2004-04-22 | — | — | US | disclosed |
| US-6706753-B2 | 2-AMINO-FLUORENE DERIVATIVES USEFUL FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH ALPHA 4 INTERGRINS OR THEIR LIGANDS | GENENTECH, INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1330430-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030129675-A1 | Assay method | GENENTECH, INC. | 2003-07-10 | — | — | US | disclosed |
| US-20030100599-A1 | 2-amino-fluorene derivatives useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with alpha 4 intergrins or their ligands | GENENTECH, INC. | 2003-05-29 | — | — | US | disclosed |
| US-20020035104-A1 | Integrin receptor inhibitors | GENENTECH, INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002016313-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
| US-20020004247-A1 | Assay method | GENENTECH, INC. | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234306-A1 | Assay method | ITGB4, ITGA4, ITGAV | ITGA4 2/4885ITGB1 8/4885POLB 3974/4885 |
| US-20040077693-A1 | Integrin receptor inhibitors | ITGB1, ITGA1, ITGA4 | ITGA4 3/4885ITGB1 1/4885POLB 4098/4885 |
| US-20050233387-A1 | Assay method | ITGB4, ITGA4, ITGAV | ITGA4 2/4885ITGB1 8/4885POLB 3974/4885 |
| US-20020035104-A1 | Integrin receptor inhibitors | ITGB1, ITGA1, ITGA4 | ITGA4 3/4885ITGB1 1/4885POLB 4098/4885 |
| US-20050187284-A1 | Integrin receptor inhibitors | ITGA4, ITGB4, ITGB1 | ITGA4 1/4885ITGB1 3/4885POLB 4185/4885 |
| US-20030100599-A1 | 2-amino-fluorene derivatives useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with alpha 4 intergrins or their ligands | ITGA1, ITGA2, ITGB1 | ITGA4 4/4885ITGB1 3/4885POLB 3296/4885 |
| US-20030129675-A1 | Assay method | ITGB4, ITGA4, ITGB6 | ITGA4 2/4885ITGB1 6/4885POLB 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.